{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T14:48:54Z","timestamp":1769093334527,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jtct.2022.08.017","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T01:55:31Z","timestamp":1661133331000},"page":"754-759","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Successful Mobilization of Autologous Hematopoietic Peripheral Blood Stem Cells after Salvage Chemotherapy in Patients with Low CD34 Blood Cell Counts"],"prefix":"10.1016","volume":"28","author":[{"given":"Leona A.","family":"Holmberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Linenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Connelly-Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.08.017_bib0001","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/bmt.2010.78","article-title":"Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization","volume":"46","author":"Costa","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.08.017_bib0002","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00277-007-0286-6","article-title":"Kinetics of CXCR-4 and adhesion molecule expression during autologous stem cell mobilisation with G-CSF plus AMD3100 in patients with multiple myeloma","volume":"86","author":"Oelschlaegel","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.08.017_bib0003","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0014-5793(02)03143-5","article-title":"Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4","volume":"527","author":"Hatse","year":"2002","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jtct.2022.08.017_bib0004","doi-asserted-by":"crossref","first-page":"14153","DOI":"10.1074\/jbc.M010429200","article-title":"Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor","volume":"276","author":"Gerlach","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jtct.2022.08.017_bib0005","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.4049\/jimmunol.166.8.5027","article-title":"CXCR-4 desensitization is associated with tissue localization of hemopoietic progenitor cells","volume":"166","author":"Shen","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.jtct.2022.08.017_bib0006","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1385\/IR:32:1-3:169","article-title":"Neutrophil homeostasis: a new role for stromal cell-derived factor-1","volume":"32","author":"Link","year":"2005","journal-title":"Immunol Res"},{"key":"10.1016\/j.jtct.2022.08.017_bib0007","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature12984","article-title":"The bone marrow niche for haematopoietic stem cells","volume":"505","author":"Morrison","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jtct.2022.08.017_bib0008","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.it.2013.10.002","article-title":"Regulation of hematopoietic stem cells by bone marrow stromal cells","volume":"35","author":"Anthony","year":"2014","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jtct.2022.08.017_bib0009","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/bmt.2008.409","article-title":"Rescue from failed growth factor and\/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience","volume":"43","author":"Fowler","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.08.017_bib0010","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/sj.bmt.1705908","article-title":"AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and\/or cytokine treatment: compassionate use data","volume":"41","author":"Calandra","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.08.017_bib0011","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.bbmt.2013.01.005","article-title":"Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells","volume":"19","author":"Maziarz","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.08.017_bib0012","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41409-017-0033-0","article-title":"Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis","volume":"53","author":"Mohty","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.08.017_bib0013","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/jca.21206","article-title":"The effective use of plerixafor as a real-time rescue strategy for patients poorly mobilizing autologous CD34(+) cells","volume":"27","author":"Gopal","year":"2012","journal-title":"J Clin Apher"},{"key":"10.1016\/j.jtct.2022.08.017_bib0014","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/trf.12813","article-title":"Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma","volume":"55","author":"Cheng","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.jtct.2022.08.017_bib0015","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1182\/blood-2011-06-318220","article-title":"How I treat patients who mobilize hematopoietic stem cells poorly","volume":"118","author":"To","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.08.017_bib0016","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000435769","article-title":"Plerixafor (Mozobil): A Stem Cell-Mobilizing Agent for Transplantation in Lymphoma Patients Predicted to Be Poor Mobilizers - A Pilot Study","volume":"135","author":"Danylesko","year":"2016","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jtct.2022.08.017_bib0017","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41409-018-0228-z","article-title":"Plerixafor in non-Hodgkin's lymphoma patients: a German analysis of time, effort and costs","volume":"54","author":"Hubel","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.08.017_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2021.103170","article-title":"Successful autologous peripheral blood stem cell collection using large volume leukapheresis in patients with very low or undetectable peripheral blood CD34+ progenitor cells","volume":"60","author":"Destrampe","year":"2021","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jtct.2022.08.017_bib0019","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.bbmt.2011.06.003","article-title":"Limiting the daily total nucleated cell dose of cryopreserved peripheral blood stem cell products for autologous transplantation improves infusion-related safety with no adverse impact on hematopoietic engraftment","volume":"18","author":"Khera","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.08.017_bib0020","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1200\/JCO.1995.13.10.2547","article-title":"Factors that influence collection and engraftment of autologous peripheral-blood stem cells","volume":"13","author":"Bensinger","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.08.017_bib0021","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/bmt.2009.370","article-title":"Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma","volume":"45","author":"Gertz","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.08.017_bib0022","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.bbmt.2013.05.008","article-title":"Pharmacoeconomics of hematopoietic stem cell mobilization: an overview of current evidence and gaps in the literature","volume":"19","author":"Shaughnessy","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.08.017_bib0023","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/sj.bmt.1705708","article-title":"Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma","volume":"40","author":"Tomblyn","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.08.017_bib0024","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/1042819031000067585","article-title":"Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation","volume":"44","author":"Gordan","year":"2003","journal-title":"Leuk Lymphoma"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722015585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722015585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:06:02Z","timestamp":1763003162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722015585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2666636722015585"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.08.017","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful Mobilization of Autologous Hematopoietic Peripheral Blood Stem Cells after Salvage Chemotherapy in Patients with Low CD34 Blood Cell Counts","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.08.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}